Gland Pharma Limited (NSE:GLAND)
India
· Delayed Price · Currency is INR | Market Cap | 300.22B |
| Revenue (ttm) | 61.13B |
| Net Income (ttm) | 8.47B |
| Shares Out | 164.76M |
| EPS (ttm) | 51.42 |
| PE Ratio | 35.44 |
| Forward PE | 28.13 |
| Dividend | 18.00 (0.99%) |
| Ex-Dividend Date | Aug 14, 2025 |
| Volume | 118,033 |
| Average Volume | 102,732 |
| Open | 1,855.00 |
| Previous Close | 1,861.20 |
| Day's Range | 1,808.80 - 1,855.00 |
| 52-Week Range | 1,277.80 - 2,131.00 |
| Beta | 0.41 |
| RSI | 51.46 |
| Earnings Date | May 20, 2026 |
About Gland Pharma
Gland Pharma Limited engages in manufacturing and sale of injectable formulations in India, the United States, Europe, Canada, Australia, New Zealand, and internationally. It engages in research and development of pharmaceutical active pharmaceutical ingredient products, including synthesis of complex drug molecules, such as low molecular weight heparins, corticosteroids, peptides, and cytotoxic molecules. The company also offers its products for various therapeutic categories, such as anti- diabetic, anti-malarial, anti-infectives, anti-neopla... [Read more]
Financial Performance
In fiscal year 2025, Gland Pharma's revenue was 56.17 billion, a decrease of -0.85% compared to the previous year's 56.65 billion. Earnings were 6.99 billion, a decrease of -9.57%.
Financial StatementsNews
Pharma sector stocks down today, Feb 24: AstraZeneca Pharma falls 1.72%, Alembic Pharma down 1.38%, Gland Pharma drops 1.24%
The Indian pharmaceutical sector experienced a modest decline on February 24, 2026, amid broader market weakness. The S&P BSE HEALTHCARE...
Gland Pharma gets USFDA nod for Zoledronic Acid Injection for US market
Gland Pharma Limited has received approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug...
Gland Pharma shares rally sharply over 8% as Q3 revenue rises 22.5% YoY to Rs Rs 1,695 crore, net profit up 27.7%
Gland Pharma shares surged over 8% in early morning trade after the company reported a strong set of consolidated results...
Top stocks for trade today, Jan 29: Wipro, Mahindra, Garden Reach, Gland Pharma, Larsen & Toubro and more
Indian equities are likely to see stock-specific action today, January 29, as several companies announced quarterly results, partnerships, and order...
Gland Pharma Ltd (NSE:GLAND) Q3 2026 Earnings Call Highlights: Strong Revenue Growth and ...
Gland Pharma Ltd (NSE:GLAND) Q3 2026 Earnings Call Highlights: Strong Revenue Growth and Strategic Expansions
Q3 2026 Gland Pharma Ltd Earnings Call Transcript
Q3 2026 Gland Pharma Ltd Earnings Call Transcript
Gland Pharma Q3 Results: Revenue jumps 22.5% YoY to Rs 1,695 crore, net profit up 27.5% YoY
Gland Pharma has announced its Q3 financial results, reporting strong year-on-year growth across key operational and profitability metrics, supported by...
Gland Pharma Ltd (NSE:GLAND) Q3 2026 Earnings Report Preview: What To Expect
Gland Pharma Ltd (NSE:GLAND) Q3 2026 Earnings Report Preview: What To Expect
Pharma sector stocks today, Jan 23: Dr. Reddy’s Lab jumps 2.14%, Gland Pharma falls 1.71%, Torrent Pharma down 0.80%
The Indian pharma sector stocks showed mixed performance as of 10:20 AM IST on January 23, 2026. The broader market...
Gland Pharma shares surge nearly 4% after getting USFDA approval for Olopatadine Hydrochloride Ophthalmic Solution 0.7% (OTC)
Gland Pharma shares climbed nearly 4% after the company announced that it has received approval from the United States Food...
Top stocks to watch today, January 8: Infosys, Tata Steel, HUDCO, Gland Pharma, Angel One, Cipla and more
Indian equity markets are likely to begin Thursday’s session on a cautious note. Trends from global indices and GIFT Nifty...
Gland Pharma receives USFDA approval for Olopatadine Hydrochloride Ophthalmic Solution 0.7% (OTC)
Gland Pharma Limited, a leading injectable and ophthalmic-focused pharmaceutical company, has received approval from the United States Food and Drug...
Nomura cautious on Gland Pharma, trims estimates post Q2 miss but sees long-term visibility
Nomura has maintained its neutral rating on Gland Pharma with a target price of ₹2,000 per share after the company...
Gland Pharma Ltd (NSE:GLAND) Q2 2026 Earnings Call Highlights: Strong Revenue Growth and ...
Gland Pharma Ltd (NSE:GLAND) Q2 2026 Earnings Call Highlights: Strong Revenue Growth and Strategic Expansion
Q2 2026 Gland Pharma Ltd Earnings Call Transcript
Q2 2026 Gland Pharma Ltd Earnings Call Transcript
Gland Pharma Q2 Results: Revenue jumps 5.8% YoY to Rs 1,487 crore, net profit up 12.2%
Gland Pharma reported a steady performance in the September quarter (Q2 FY26), with moderate year-on-year growth across key financial metrics....
Gland Pharma Ltd (NSE:GLAND) Q2 2026 Earnings Report Preview: What To Expect
Gland Pharma Ltd (NSE:GLAND) Q2 2026 Earnings Report Preview: What To Expect
These Indian pharma stocks tumble as Trump announces 100% tariff on branded drugs
Indian pharmaceutical shares came under heavy selling pressure on Friday, September 26, after U.S. President Donald Trump announced a 100% tariff on branded and patented pharmaceutical drugs starting ...
Gland Pharma shares fall over 4% as Trump announces 100% tariff on pharma imports
Shares of Gland Pharma slipped 4.03% to ₹1,892.50 in Friday’s session, as investors reacted sharply to U.S. President Donald Trump’s announcement of a 100% tariff on imports of branded and patented ph...
Gland Pharma down 4%, Sun Pharma slips 2.6%, Dr Reddy’s down 2%, Zydus nearly 3%, Aurobindo down 2% as Trump’s 100% pharma tariff jolts sector
Indian pharmaceutical stocks came under heavy selling pressure on Friday, September 26, after U.S. President Donald Trump announced a 100% tariff on imports of branded and patented pharmaceutical drug...
Gland Pharma gets USFDA nod for Vasopressin in 5% Dextrose RTU Injection
Gland Pharma Limited, a Hyderabad-based generic injectable and ophthalmic-focused pharmaceutical company, announced that it has received approval from the United States Food and Drug Administration (U...
Gland Pharma gets USFDA approval for Cangrelor injection with 180-day exclusivity
Gland Pharma Limited, a leading player in the generic injectable and ophthalmic pharmaceutical space, has received the green light from the United States Food and Drug Administration (USFDA) for its A...
Gland Pharma shares jump 4% as Q1 revenue rises 7% YoY to Rs 1,505.6 crore, net profit up 50% YoY
Gland Pharma shares climbed over 4% in early trade on Wednesday after the company reported strong financial results for the first quarter of FY26. The pharmaceutical major delivered robust growth acro...
Top stocks to watch today, August 6: Bharti Airtel, Lupin, Britannia, NCC, Gland Pharma and more
The Indian stock market is likely to see stock-specific action today, August 6, as several companies have announced their Q1 earnings, signed key deals, or received regulatory clearances. Here’s a qui...
Gland Pharma share: Jefferies upgrades to hold, Goldman Sachs maintains sell; divergent views on recovery and upside
Jefferies has upgraded its rating on Gland Pharma to Hold from its previous stance, with a revised target price of ₹1,970, citing operational recovery signs and a turnaround in its European subsidiary...